Paid Clinical Trials North Dakota
Discover 169 paid clinical trials in North Dakota. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Neoadjuvant Chemotherapy vs. ChemoradiotherapyNeoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Sponsor:
Canadian Cancer Trials Group
Location:
Code:
NCT06205485
Conditions
Rectal Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Leucovorin
Oxaliplatin
Fluoruracil
Capecitabine
Radiation
Observational StudyAlcohol Related Impairment and Reinforcement: Pre to Post Roux en Y Gastric Bypass Surgery
Sponsor:
Neuropsychiatric Research Institute, Fargo, North Dakota
Location:
Code:
NCT02370732
Conditions
Bariatric Surgery Candidate
Eligibility Criteria
Sex: All
Age: 21 - 65
Healthy Volunteers: Accepted
Interventions
Alcohol
LutikizumabA Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Sponsor:
AbbVie
Location:
Code:
NCT06257875
Conditions
Ulcerative Colitis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Lutikizumab Matching Placebo
Adalimumab Matching Placebo
Lutikizumab
Adalimumab
Pembrolizumab & Sacituzumab TirxumotecanA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06312137
Conditions
Non Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sacituzumab tirumotecan
Pembrolizumab
Cisplatin
Pemetrexed
Gemcitabine
Interested in new trials?
Get alerts for new trials in your area by subscribing now
PembrolizumabKEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT04165070
Conditions
Carcinoma, Non-Small-Cell Lung
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Carboplatin
Paclitaxel
Pemetrexed
Vibostolimab
RavulizumabARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Sponsor:
Alexion Pharmaceuticals, Inc.
Location:
Code:
NCT05746559
Conditions
Chronic Kidney Disease
CKD
Cardiac Disease
Cardiopulmonary Bypass
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Ravulizumab
DupilumabEvaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
Sponsor:
Andover Eye Associates
Location:
Code:
NCT04296864
Conditions
Atopic Keratoconjunctivitis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Dupilumab
TozorakimabLong-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Sponsor:
AstraZeneca
Location:
Code:
NCT05742802
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
Tozorakimab 1
Tozorakimab 2
Placebo
LunsekimigA Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Sponsor:
Sanofi
Location:
Code:
NCT06790121
Conditions
Dermatitis Atopic
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Lunsekimig
Placebo